<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4973">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05096468</url>
  </required_header>
  <id_info>
    <org_study_id>Z19110000661906703</org_study_id>
    <nct_id>NCT05096468</nct_id>
  </id_info>
  <brief_title>Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.</brief_title>
  <official_title>Esketamine Combined With Pregabalin on Acute Postoperative Pain in Patients Undergoing Resection of Spinal Neoplasms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postsurgical pain is now known to be one of the most common and difficult-to-treat&#xD;
      complications of surgery. severe postoperative pain can significantly impair patients'&#xD;
      quality of life, social functioning and contribute to excessive health care expenditures. It&#xD;
      is worth noting that acute postoperative pain may play a vital role in central sensitization&#xD;
      and up-regulation of pain receptors, even factors implicated in the development of CPSP.&#xD;
      According to previous studies, the incidence of postoperative pain among patients undergoing&#xD;
      spinal surgery was nearly 80%. At the same time, perioperative pain management of patients&#xD;
      undergoing spinal surgery has not been clearly. For the past few years, pregabalin and&#xD;
      esketamine are becoming important roles in perioperative pain management, lots of studies&#xD;
      have shown that these two analgesics might relieve postoperative pain. The aim of this study&#xD;
      was to evaluate the acute analgesic effects of esketamine and pregabalin in combination after&#xD;
      spinal cord neoplasms resection, so as to find a better way to help the patients undergoing&#xD;
      spinal surgery keep away from the acute perioperative pain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with acute moderate-to-severe postsurgical pain during 48h after operation</measure>
    <time_frame>48 hours after operation</time_frame>
    <description>The primary outcome was the proportion of patients with acute moderate-to-severe postsurgical pain during the 48-h postoperative period (defined as a VAS score â‰¥ 40 mm).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Esketamine</condition>
  <condition>Pregabalin</condition>
  <condition>Acute Postoperative Pain</condition>
  <condition>Neurosurgical Procedures</condition>
  <condition>Perioperative Complication</condition>
  <condition>Spinal Cord Neoplasms</condition>
  <arm_group>
    <arm_group_label>S-ketamine and pregabalin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline and placebo capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-ketamine and pregabalin</intervention_name>
    <description>Drug: Pregabalin&#xD;
150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7), followed by dose reduction to 75mg once daily for 7 days(POD8-14)&#xD;
Drug: S-ketamine infusion&#xD;
0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h</description>
    <arm_group_label>S-ketamine and pregabalin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline and placebo capsule</intervention_name>
    <description>Drug: Placebo capsules&#xD;
Two placebo capsules (2hrs) preoperatively and twice daily post operatively for 7days, followed by dose reduction to single capsule once daily for 7days&#xD;
Drug: Normal saline&#xD;
0.9% saline bolus after induction of anesthesia + intravenous infusion for 48 hours</description>
    <arm_group_label>Normal saline and placebo capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient undergoing elective spinal cord neoplasms resection;&#xD;
&#xD;
          -  Ages between 18 and 65 years old;&#xD;
&#xD;
          -  American Society of Anaesthesiology (ASA) status I-III;&#xD;
&#xD;
          -  Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous adverse reaction to ketamine, s-ketamine or pregabalin;&#xD;
&#xD;
          -  Patients with a diagnosed history of severe chronic pain;&#xD;
&#xD;
          -  Patients with long-term analgesic treatment(gabapentin/opioids/ketamine);&#xD;
&#xD;
          -  Patients with aphasia or inability to cooperate with the pain assessments;&#xD;
&#xD;
          -  Known sever insufficiency of vitals(such as heart failure/renal dysfunction/hepatic&#xD;
             failure);&#xD;
&#xD;
          -  Patients with a diagnosed history of psychiatric disorder;&#xD;
&#xD;
          -  Patients treated with gabapentin/pregabalin in the last three months;&#xD;
&#xD;
          -  Drug abuse;&#xD;
&#xD;
          -  Body mass index (BMI) &gt; 35 kg/m2 ;&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Tiantan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ruquan Han, M.D., Ph D.</last_name>
    <phone>8610-59976660</phone>
    <email>ruquan.han@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing TianTan Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruquan Han, M.D., Ph.D</last_name>
      <phone>8610-59976660</phone>
      <email>ruquan.han@ccmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2021</study_first_posted>
  <last_update_submitted>November 27, 2021</last_update_submitted>
  <last_update_submitted_qc>November 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Ruquan Han</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Spinal Cord Neoplasms</mesh_term>
    <mesh_term>Spinal Neoplasms</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregabalin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Esketamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

